Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

20. September 2018 07:30 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Host Analyst and Investor Symposium on Portal Hypertension

SAN DIEGO, Sept. 20, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, will host an...
19. September 2018 07:30 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Participate in Upcoming Investor Conferences

SAN DIEGO, Sept. 19, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) has accepted invitations to participate in two upcoming investor conferences. At the Oppenheimer Fall Summit...
29. August 2018 07:30 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Present at BioCentury NewsMakers Conference

SAN DIEGO , Aug. 29, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
01. August 2018 16:05 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports Second Quarter 2018 Financial Results and Program Updates

SAN DIEGO, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...
25. Juli 2018 16:05 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report Second Quarter 2018 Financial Results

SAN DIEGO , July 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the second quarter ended June 30, 2018, after the...
02. Juli 2018 07:30 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals’ Pan-caspase Inhibitor Emricasan Improves Survival and Portal Hypertension in a Mouse Model of Cirrhosis

SAN DIEGO, July 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the publication1 of results from preclinical studies of its pan-caspase inhibitor emricasan,...
02. Mai 2018 16:05 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals Reports First Quarter 2018 Financial Results and Program Updates

SAN DIEGO, May 02, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development of novel medicines to treat liver disease, today announced...
30. April 2018 07:30 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Announces Completion of Enrollment in ENCORE-PH Phase 2b Clinical Trial of Emricasan in Patients with NASH Cirrhosis and Severe Portal Hypertension

SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced the completion of enrollment in ENCORE-PH, a Phase 2b clinical trial evaluating emricasan,...
25. April 2018 16:05 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals to Report First Quarter 2018 Financial Results

SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT) today announced that it will report financial results for the first quarter ended March 31, 2018, after the...
18. April 2018 07:30 ET | Quelle: Conatus Pharmaceuticals Inc.

Conatus Pharmaceuticals’ IDN-7314 Pan-caspase Inhibitor Reduces Hepatic Tissue Factor-Driven Coagulation In Vitro and In Vivo

SAN DIEGO, April 18, 2018 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver...

Vorherige Seite

Nächste Seite